Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell p… Read more
Cellectis SA (CLLS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.016x
Based on the latest financial reports, Cellectis SA (CLLS) has a cash flow conversion efficiency ratio of -0.016x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.57 Million) by net assets ($100.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cellectis SA - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Cellectis SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cellectis SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectis SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Formosa Laboratories Inc
TW:4746
|
0.032x |
|
Taekwang Ind
KO:003240
|
-0.011x |
|
Nam Tai Property Inc.
PINK:NTPIF
|
-0.013x |
|
Elme Communities
NYSE:ELME
|
0.018x |
|
HKFoods Oyj A
HE:HKFOODS
|
0.013x |
|
Mildef Crete
TWO:3213
|
0.032x |
|
PASONA GROUP INC.
F:9D4
|
N/A |
|
GigCapital7 Corp. Class A Ordinary Share
NASDAQ:GIG
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Cellectis SA (2007–2024)
The table below shows the annual cash flow conversion efficiency of Cellectis SA from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $131.03 Million | $22.10 Million | 0.169x | +157.73% |
| 2023-12-31 | $84.69 Million | $-24.75 Million | -0.292x | +57.92% |
| 2022-12-31 | $125.94 Million | $-87.44 Million | -0.694x | -57.03% |
| 2021-12-31 | $236.47 Million | $-104.56 Million | -0.442x | -70.15% |
| 2020-12-31 | $308.85 Million | $-80.26 Million | -0.260x | -33.61% |
| 2019-12-31 | $355.47 Million | $-69.14 Million | -0.195x | -28.54% |
| 2018-12-31 | $450.27 Million | $-68.14 Million | -0.151x | +17.32% |
| 2017-12-31 | $285.90 Million | $-52.33 Million | -0.183x | -61.34% |
| 2016-12-31 | $274.05 Million | $-31.09 Million | -0.113x | -1024.12% |
| 2015-12-31 | $288.22 Million | $3.54 Million | 0.012x | -98.25% |
| 2014-12-31 | $72.39 Million | $50.74 Million | 0.701x | +118.19% |
| 2013-12-31 | $6.65 Million | $-25.63 Million | -3.854x | -1105.67% |
| 2012-12-31 | $81.69 Million | $-26.11 Million | -0.320x | +10.29% |
| 2011-12-31 | $37.02 Million | $-13.19 Million | -0.356x | +15.35% |
| 2010-12-31 | $50.13 Million | $-21.10 Million | -0.421x | -337.25% |
| 2009-12-31 | $73.22 Million | $-7.05 Million | -0.096x | -350.06% |
| 2008-12-31 | $46.21 Million | $1.78 Million | 0.038x | +129.82% |
| 2007-12-31 | $43.54 Million | $-5.62 Million | -0.129x | -- |